Market Research Logo

Insulin Market in Europe 2015-2019

Insulin Market in Europe 2015-2019

About insulin

Insulin is a hormone produced by the beta cells of the pancreas; insulin has a key role in regulating the blood glucose levels. It regulates the metabolism of glucose and other nutrients in the body. Insulin permits the body to utilize sugar (glucose) from carbohydrates in the food for energy or to store glucose for future use. The beta cells of the pancreas of people with type 1 diabetes do not produce sufficient insulin to regulate blood glucose level; therefore, they need to intake insulin daily. On the other hand, people with type 2 diabetes or gestational diabetes need doses of insulin together with other medication. Different type of insulin such as human insulin and insulin analogs are available for insulin replacement therapy.

Technavio's analysts forecast the insulin market in Europe to grow at a CAGR of 6.50% over the period 2014-2019.

Covered in this report

The report covers the present scenario and the growth prospects of the insulin market in Europe for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various insulin used for the treatment of diabetes.

Technavio's report, Insulin Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the insulin market in Europe and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key vendors

  • Elli Lilly
  • Novo Nordisk
  • Sanofi
Other prominent vendors
  • Biodel
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Diamyd Medical
  • DiaVacs
  • Generex Biotechnology
  • Lexicon Pharmaceuticals
  • Macrogenics
  • Merck
  • Osiris Therapeutics
  • Pfizer
  • Tolerion
  • XOMA
Key market driver
  • Increase in prevalence of diabetes
  • For a full, detailed list, view our report
Key market challenge
  • Stringent regulatory environment
  • For a full, detailed list, view our report
Key market trend
  • Rise in awareness programs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Insulin Market in Europe 2015-2019

Technavio recognizes the following companies as the key players in the Insulin Market in Europe: Eli Lilly and Co., Novo Nordisk A/S and Sanofi SA

Other Prominent Vendors in the market are: Biodel, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals, Macrogenics, Merck, Osiris Therapeutics, Tolerion and XOMA

Commenting on the report, an analyst from Technavio’s team said: “Growing public awareness of diabetes and the available treatments will likely increase the number of people opting for these treatments. Healthcare companies are organizing awareness camps and discussions to educate people about the condition. These are conducted either alone or in combination with other national institutes.”

According to the report, changing lifestyle, consumption of high-fat-containing foods, and reduced physical activity increase the prevalence of obesity among the population. Obesity affects the body's normal metabolism, triggering the adipose tissues to release increased amounts of fatty acids, hormones, pro-inflammatory cytokines, and other factors, which are involved in insulin resistance.

Further, the report states that the development and regulatory approval of biologic insulin and insulin analog products take longer than small molecules. Minor alterations in the physical structure and chemical pattern can significantly alter the safety and efficacy of these moieties. Unnoticeable variations in the design and execution of a manufacturing process can alter the pharmacokinetic and pharmacodynamics profiles of a drug.

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Product Profiles
    • Humalog
    • Liprolog
    • Actrapid
    • Levemir
    • NovoMix
    • NovoRapid
    • Tresiba
    • Apidra
    • Insuman
    • Lantus
    • Toujeo
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Insulin: An Overview
    • Product Portfolio
    • Epidemiology
      • Table Number of People Aged 20-79 with Diabetes in Europe 2013 and 2035 (millions)
      • Table Percentage of People Aged 20-79 with Diabetes in Europe 2013 and 2035
      • Table Percentage of Undiagnosed People Aged 20-79 with Diabetes in Europe by Income 2013
      • Table Top Four Countries in Europe with High Proportion of Diabetic People 2013 (millions)
      • Table Few Countries in Europe with High Proportion of Diabetic People Aged 20-79 by Gender 2014
    • Pipeline Portfolio
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Insulin Market in Europe 2014-2019 ($ millions)
    • Five Forces Analysis
  • Market Segmentation by Type
    • Table Segmentation of Insulin Market in Europe by Type
    • Fast-acting Insulin
      • Rapid-acting Insulin
      • Regular Human Insulin
    • Intermediate-acting Insulin
      • NPH Human Insulin
      • Pre-mixed Insulin
    • Long-acting Insulin
  • Buying Criteria
  • Market Growth Drivers
    • Table Major Drivers of Insulin Market in Europe
    • Table Percentage of People with Diabetes in 28 Member Countries in EU by Age Group 2013-2040
    • Table Percentage of People with Diabetes in Few European Countries by Age Group 2014
    • Table Factors Influencing Development of Insulin Delivery Devices
  • Drivers and Their Impact
  • Market Challenges
    • Table Diabetes Rule of Halves
    • Table Number of Diabetes and Undiagnosed Diabetes Cases in Few European Countries Among People Aged 20-79 2014
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and Their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Table Ranking of Top Vendors
      • Novo Nordisk
        • Table Novo Nordisk: Revenue of Insulin Products in Europe 2011-2014 ($ millions)
        • Table Novo Nordisk: YoY Growth and Revenue of NovoRapid in Europe 2011-2014 ($ millions)
        • Table Novo Nordisk: YoY Growth and Revenue of NovoMix in Europe 2011-2014 ($ millions)
        • Table Novo Nordisk: YoY Growth and Revenue of Levemir in Europe 2011-2014 ($ millions)
        • Table Novo Nordisk: YoY Growth and Revenue of Human Insulins in Europe 2011-2014 ($ millions)
      • Sanofi
        • Table Sanofi: YoY Growth and Revenue of Lantus in Western Europe 2011-2014 ($ millions)
        • Table Sanofi: YoY Growth and Revenue of Apidra in Western Europe 2011-2014 ($ millions)
        • Table Sanofi: YoY Growth and Revenue of Insuman in Western Europe 2011-2014 ($ millions)
      • Eli Lilly
    • Other Prominent Vendors
  • Key Vendor Analysis
    • Eli Lilly
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue
        • Table Eli Lilly: Business Segmentation by Revenue 2013
        • Table Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ millions)
      • Sales by Geography
        • Table Eli Lilly: Sales by Geography 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Novo Nordisk
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Novo Nordisk: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Novo Nordisk: Business Segmentation by Revenue 2012 and 2013 ($ billions)
      • Sales by Geography
        • Table Novo Nordisk: Sales by Geography 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
      • Strengths
      • Weakness
      • Opportunities
      • Threats
    • Sanofi
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Sanofi: Business Segmentation
      • Revenue by Business Segmentation
        • Table Sanofi: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Sanofi: Revenue by Business Segmentation 2012 and 2013 ($ millions)
      • Sales by Geography
        • Table Sanofi: Sales Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in This Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report